GW Pharma to File Cannabis Drug as Epilepsy Success Confirmed

By:
GW Pharma to File Cannabis Drug as Epilepsy Success Confirmed

Flickr / Cannabis Pictures / (CC BY 2.0)

GW Pharmaceuticals is set to file its cannabis-derived drug with U.S. regulators imminently, following publication of detailed data on its success in fighting severe childhood epilepsy.

GW first reported in March 2016 that Epidiolex cut monthly convulsive seizures by 39 percent in children with Dravet syndrome, but full results of the 120-patient study were only published in the New England Journal of Medicine on Wednesday.

The journal article also showed that 5 percent of patients stopped having seizures altogether.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts

Top